Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer
2017; Massachusetts Medical Society; Volume: 376; Issue: 5 Linguagem: Inglês
10.1056/nejmoa1607529
ISSN1533-4406
AutoresWilliam U. Shipley, Wendy Seiferheld, Himanshu Lukka, Pierre Major, Niall M. Heney, David J. Grignon, Oliver Sartor, Maltibehn P. Patel, Jean-Paul Bahary, Anthony L. Zietman, Thomas M. Pisansky, Kenneth L. Zeitzer, C.A. Lawton, Felix Y. Feng, R.D. Lovett, Alexander G. Balogh, Luís Souhami, Seth A. Rosenthal, K. Kerlin, James J. Dignam, Stephanie L. Pugh, Howard M. Sandler,
Tópico(s)Cancer, Lipids, and Metabolism
ResumoSalvage radiation therapy is often necessary in men who have undergone radical prostatectomy and have evidence of prostate-cancer recurrence signaled by a persistently or recurrently elevated prostate-specific antigen (PSA) level. Whether antiandrogen therapy with radiation therapy will further improve cancer control and prolong overall survival is unknown.
Referência(s)